Disipan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Disipan

Quick Facts

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Form Versatile (oral, injectable solution, topical gel, suppository)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Relieves pain, reduces inflammation, lowers fever
Origin Synthetic (phenylacetic acid derivative)

Disipan: Definition and Pharmacological Classification

Disipan is a prescription-only medicinal preparation defined by its single active ingredient, Diclofenac, which is typically utilized as a salt, such as Diclofenac sodium or Diclofenac potassium, to ensure optimal pharmaceutical performance. The drug belongs to the widely recognized Non-steroidal Anti-inflammatory Drug (NSAID) class. Structurally, Diclofenac is a synthetic compound categorized as a phenylacetic acid derivative. This medication functions systemically by inhibiting the cyclooxygenase (COX) enzymes, a mechanism that centrally controls the production of prostaglandins, the chemical mediators responsible for transmitting pain signals and triggering inflammation. Disipan is distinctively positioned for systemic use, offering a powerful option for patients requiring comprehensive pain management beyond topical application.

Composition, Forms, and General Purpose

As a versatile agent, Disipan utilizes the active compound, Diclofenac, in diverse dosage forms tailored for patient needs, which include solid oral forms like tablets and capsules, parenteral solutions for injection, rectal suppositories, and topical preparations such as gels. Diclofenac effectively decreases pain and swelling in the body, providing a general therapeutic benefit. This anti-inflammatory and analgesic efficacy is clinically recognized for conditions associated with chronic musculoskeletal discomfort. The general therapeutic purpose of Disipan is to offer a comprehensive dual benefit, providing a significant analgesic (pain-relieving) effect and a robust anti-inflammatory effect, alongside an antipyretic (fever-reducing) capability. This inherent ability to modulate the body's primary inflammatory and pain processes is the defining feature of its clinical utility across various routes of administration.

What side effects are possible with Disipan?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety constraints of Disipan as documented in official government regulatory labeling. The information is organized by frequency and the body system affected.

Adverse Reactions by Frequency

Frequency Category Examples of Reported Adverse Reactions
Very Common (ge 1/10) Headache, Nausea, Diarrhea
Common (ge 1/100 to < 1/10) Dizziness, Fatigue, Rash
Uncommon (ge 1/1,000 to < 1/100) Increased liver enzymes (ALT/AST), Urticaria
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, QT interval prolongation
Frequency Unknown Hypersensitivity reaction, Anaphylactic shock

Serious Adverse Reactions and System-Organ Classes

Serious Adverse Reactions (SARs): Regulatory documents list rare but clinically significant events including Agranulocytosis, QT Interval Prolongation/Torsades de Pointes (TdP), and Severe Hepatic Failure. Immediate attention is required if signs of severe hepatic injury or cardiac rhythm changes occur.

Affected System-Organ Classes (SOCs): Adverse reactions are documented across several systems, notably Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, Blood and Lymphatic System Disorders, and Cardiac Disorders.


Population-Specific Safety and Restrictions

Specific Patient Groups:

  • Hepatic Impairment: Disipan is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
  • Geriatric Population: An increased risk of Hypotension is noted in patients aged 75 years and older.
  • Pediatrics: Safety and efficacy are not established for patients under 12 years of age.

Safety-Related Limitations: The drug must not be used concurrently with known CYP450 3A4 inhibitors due to the risk of serious cardiac events. Mandatory baseline and regular ECG monitoring is required for patients with pre-existing cardiac conditions. Gastrointestinal adverse events are typically more common during the first two weeks of treatment initiation.

Overdose and Emergency Response

Overdose Manifestations and Actions Mandated by Regulators

Official prescribing information documents the clinical signs and symptoms that may occur following an acute overdose of Disipan (Diclofenac). Overdose may manifest as gastrointestinal symptoms, including nausea, vomiting, stomach pain (epigastric pain), and diarrhea. Central nervous system effects such as dizziness, headache, and somnolence are also listed in regulatory labeling.

Regulatory authorities classify severe overdose as potentially life-threatening due to the documented risk of acute renal failure, hepatic dysfunction, and serious gastrointestinal complications, including bleeding or perforation. In very severe cases, seizures and coma have been reported.

Emergency Response and Supportive Care

The official instruction is to seek immediate medical attention or contact Emergency Services right away upon suspicion of an overdose. Urgent help is explicitly required if severe symptoms, such as signs of internal bleeding or seizures, occur. Regulatory documents confirm that no specific antidote is known for Diclofenac overdose. Therefore, treatment is explicitly defined as symptomatic and supportive care, which may include procedures like gastric lavage or activated charcoal administration, depending on the patient's presentation and the time of ingestion. Hospital monitoring may be required for observation of critical organ function. Elderly patients and those with pre-existing renal or hepatic impairment are noted to be at increased risk for serious outcomes.

Therapeutic Uses of Disipan

Disipan (Diclofenac) is commonly used to provide supportive symptomatic relief across key domains characterized by symptoms related to inflammatory or irritative states and pain. Its main use is to provide supportive relief to help ease the symptom burden associated with conditions where symptoms may intensify temporarily.

This medication is relevant for a variety of conditions, including Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, acute discomfort following surgical operations or injury (e.g., sprains and strains), migraine headaches, and Primary Dysmenorrhea.


Therapeutic Contexts and Support

Disipan is considered relevant for long-term conditions and acute episodes alike. It addresses persistent symptoms of joint pain, stiffness, and swelling that create noticeable interference with daily functioning, and may assist with maintaining functional stability. It is relevant when acute manifestations of pain disrupt daily routine, and is relevant when short-term symptomatic assistance is needed to help ease the overall symptom load.

“Disipan is applied in scenarios where additional management of discomfort is required, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Addressing Pain and Inflammation
Symptom Axis Pain, Swelling, Stiffness, Fever
Use Category Symptomatic Support
Contexts Chronic, Acute, Episodic Manifestations
Key Therapeutic Role Contributes to improved day-to-day comfort

The medication is applicable in clinical settings marked by the dual patient distress of pain and fever, offering symptomatic relief and supporting patients during difficult, recurrent episodes by easing distress. It contributes to easing the overall symptom load across conditions characterized by episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Diazepam

This section outlines the eligibility criteria and restrictions for use as strictly documented in official government regulatory information (e.g., FDA, EMA). Use of this medicine is defined by contraindications, age-related rules, and conditional restrictions based on pre-existing conditions.

Absolute Contraindications (Must Not Be Used)

Condition/Population Restriction Status
Known Hypersensitivity to the drug Contraindicated
Myasthenia gravis Contraindicated
Severe respiratory insufficiency Contraindicated
Severe hepatic insufficiency Contraindicated
Sleep apnoea syndrome Contraindicated
Acute narrow-angle glaucoma Contraindicated
Pediatric patients under 6 months of age Contraindicated

Conditional and Restricted Use

Use is restricted in several populations, often requiring a lower dose or close medical supervision:

  • Elderly and Debilitated Patients: A reduced dose is required to mitigate the risk of oversedation and potential harm.
  • Pregnancy and Lactation: Use during pregnancy, particularly the first and third trimesters, should be avoided or considered only when the clinical benefit outweighs the potential risk to the fetus. The drug is excreted in breast milk, and use during lactation is generally discouraged.
  • Chronic Organ Dysfunction: Patients with chronic respiratory insufficiency require a lower dosage. Patients with open-angle glaucoma may use the drug only if receiving appropriate treatment for their condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Disipan (Diclofenac) focuses on combinations that may alter drug exposure or intensify the risk of specific adverse events. The medicine is contraindicated for use in the setting of peri-operative pain management following Coronary Artery Bypass Graft (CABG) surgery.

Interaction Classification Example Interacting Substance Documented Regulatory Outcome
Additive Pharmacodynamic Risk Other systemic NSAIDs, Anticoagulants (e.g., Warfarin), SSRIs, Corticosteroids Increases the risk of serious gastrointestinal bleeding or ulceration.
Altered Drug Concentration Lithium, Digoxin, Methotrexate Can officially increase the serum concentration of the co-administered drug.
Metabolic Inhibition Voriconazole (a CYP2C9/3A4 inhibitor) Causes a significant increase in Diclofenac systemic exposure (AUC/Cmax).

Co-administration with ACE Inhibitors or Diuretics may impair renal function and reduce the antihypertensive effect, a risk noted as specifically heightened in the elderly or those with renal impairment. Concurrent use of Alcohol is also associated with an increased risk of serious gastrointestinal problems. The extent of Diclofenac absorption for most oral formulations is not significantly affected by food, according to regulatory documentation.

Mechanism of Action

Modulation of Eicosanoid Inflammatory Pathways

Disipan's primary mechanism involves competitive inhibition of Cyclooxygenase (COX) enzymes; the drug preferentially targets the COX-2 isoform that is highly expressed during inflammatory processes. This enzyme inhibition curtails the synthesis of Prostaglandins, specifically Prostaglandin E₂ (PGE₂), which are powerful chemical mediators. The resulting reduction in PGE2 concentration supports the regulation of excessive vasodilation and localized fluid leakage, resulting in the limitation of mediator-driven tissue responses.

Direct Dampening of Nociceptive Signaling

The mechanism incorporates an additional action that directly modulates the nervous system's electrical signaling. It acts through the blockade of Voltage-dependent Sodium (Na^+) channels on peripheral sensory neurons.

This action limits the necessary ion flux required to propagate an action potential, which suppresses the transmission of nociceptive impulses to the CNS. This pathway interference influences the signaling sequences that result in downstream physiological consequences.

Dosage and Administration Information

Disipan, defined by its active ingredient Diclofenac, is administered via several officially approved routes. The administration is highly dependent on the intended therapeutic goal and dosage form, encompassing oral forms (tablets, capsules, solutions), topical preparations (gels and patches), and parenteral solutions for intramuscular or intravenous use.

Usage is characterized by indication-specific dosing and frequency patterns. For the long-term management of chronic conditions such as Osteoarthritis, total daily doses typically range from 100 mg to 150 mg, often divided and taken two or three times daily. Conversely, for the intermittent management of acute painful episodes, official guidance may prescribe an initial dose of 50 mg, followed by doses up to three times a day, though not to exceed a daily maximum typically set at 150 mg. Extended-release formulations are generally taken once daily.

Specific administration rules dictate proper use. To maintain the intended drug release profile, enteric-coated and extended-release tablets must be swallowed whole and should not be crushed or chewed. Timing relative to meals is form-dependent; for instance, immediate-release forms intended for rapid systemic absorption, like the oral solution, are often instructed to be taken on an empty stomach. Furthermore, for older adults, official guidance often emphasizes initiating treatment at the lowest effective dose. The overall duration of use is constrained by the principle of utilizing the medicine for the shortest possible time necessary to address symptoms.

Recent Clinical Evidence

Overview of Clinical Research for Disipan (Diclofenac)

Research exploring Disipan (Diclofenac) is primarily conducted through Randomized Controlled Trials (RCTs) and Systematic Reviews, which examine outcomes related to systemic or functional imbalance in various conditions. This evidence is crucial to the assessments conducted by regulatory bodies such as the European Medicines Agency (EMA) and other national health authorities. The research focuses on standardized, patient-reported outcomes to characterize patterns related to symptoms studied. The findings describe group patterns and contribute to the broader evidence landscape. Research does not determine whether an individual will respond similarly.


Evidence for Use in Chronic Inflammatory Conditions

Studies Investigating Symptoms in Osteoarthritis

Research for Osteoarthritis (OA) has primarily used short- to intermediate-term RCTs that compare the formulation to a placebo or other treatments. The study outcomes examined were patient-reported outcomes describing perceived discomfort, specifically changes measured in pain intensity and physical function over observation periods typically lasting up to 12 weeks. Findings describe patterns observed in these studies, where measured scores for pain and physical function often described measured differences between the observed groups. These study results apply only to the populations studied and do not provide definitive individual predictions.

Studies Investigating Symptoms in Rheumatoid Arthritis and Ankylosing Spondylitis

Research for these conditions consists of RCTs and studies where the Diclofenac formulation was observed alongside other Non-steroidal Anti-inflammatory Drugs (NSAIDs). Researchers examine outcomes related to physical discomfort, such as tender and swollen joint counts, alongside patient-reported pain scales and assessments of functional capacity. One major two-year RCT explored outcomes related to radiographic progression (changes in the spine as seen on X-rays) in patients with Ankylosing Spondylitis (AS). Research exploring radiographic progression in AS described patterns that did not indicate measured differences.


What the Research Landscape Does Not Yet Characterize

It is important to understand what the research does not currently provide insight into regarding Disipan. The research focuses on outcomes related to physical discomfort and does not characterize any ability to slow or reverse the underlying progression of chronic diseases. High-quality, double-blind RCTs evaluating the consistent maintenance of symptomatic improvement beyond one year are generally lacking in the evidence base, meaning data are still emerging in this area.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline [CG179]: Rheumatoid arthritis in adults: management
  2. MedlinePlus Drug Information: Diclofenac (Oral route)

Frequently Asked Questions (FAQ)

Common questions about Disipan (FAQ)


Q: How long does it usually take to notice any effect from Disipan?

Official product information suggests that for the relief of acute pain, the initial effects of oral forms may be noticed within 20 to 30 minutes. Achieving the full anti-inflammatory benefit for chronic conditions may require taking the medication consistently for up to a week or longer to become apparent.


Q: What should I do if I miss a dose of Disipan?

Official patient instructions state that if a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. The guidance advises skipping the missed dose in that instance, and cautioning against taking a double dose to compensate.


Q: How quickly does Disipan leave the body?

Pharmacokinetic data from regulatory documents indicates that the terminal half-life of the unchanged drug is approximately 2 hours. The half-life is a measure of how quickly the body eliminates half of the remaining drug.


Q: Is Disipan considered a controlled substance?

Disipan is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official governmental classifications do not list it as a controlled substance.


Q: Is Disipan effective for mild symptoms?

The drug is indicated for the relief of signs and symptoms of specific conditions, as outlined in official labeling. Regulatory guidance emphasizes using the lowest effective dose for the shortest duration necessary to control symptoms.


Q: Are the common side effects of Disipan temporary?

Official patient information notes that common side effects, such as dizziness or feeling unsteady, may improve as the body adjusts to the medication. These effects are often temporary and may wear off after treatment begins.


Q: Will Disipan make me feel drowsy or tired?

Regulatory documents list side effects such as somnolence (sleepiness), tiredness (asthenia), or dizziness as possible adverse reactions. Official warnings state that if these effects are experienced, using heavy machinery or driving should be avoided until the effects have passed.


Q: Can Disipan be taken by children or teenagers?

The safety and effectiveness of the drug have not been established for all pediatric patient groups. Specific oral formulations are often restricted from use in adolescents below a certain age, such as 14 years, as noted in official prescribing information.


Q: Does the time of day matter when taking Disipan?

Timing is sometimes related to symptom profile. Regulatory documents indicate that for certain conditions where symptoms are most pronounced during the night or in the morning, the medication may be administered in the evening.


Q: Are there any specific laboratory tests required while taking Disipan?

Official regulatory guidance states that during prolonged treatment, regular monitoring of blood count, hepatic (liver) function, and renal (kidney) function is considered a necessary precautionary measure.


Q: Are allergic reactions to Disipan common?

Official safety information lists serious, potentially fatal, allergic reactions, including anaphylaxis, as possible adverse events, though these may be rare. The drug is strictly contraindicated in patients who have experienced asthma, hives (urticaria), or acute nasal inflammation (rhinitis) after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: Does alcohol change how Disipan works in the body?

Official regulatory warnings focus on safety. Concurrent use of alcohol while taking this medicine may significantly increase the risk of serious gastrointestinal adverse events, such as stomach bleeding.


Q: Can people with kidney problems use Disipan?

The official prescribing information indicates that the drug is generally not recommended and is often contraindicated in people with severe or advanced renal (kidney) impairment. This restriction is in place due to the risk of worsening kidney function.


Q: What does 'contraindication' mean in the context of Disipan?

A contraindication is a specific condition or circumstance in which the use of the drug is forbidden. Regulatory documents list these restrictions because the risks of administering the medicine in that setting are generally considered to outweigh any potential therapeutic benefits.


Q: Does taking Disipan affect my ability to drive or operate machinery?

Official regulatory documentation states that the medicine may cause adverse reactions such as dizziness or light-headedness. Patients are warned that caution is necessary and activities like driving or operating machinery should be avoided until the individual is aware of how the drug affects them.


Q: Does Disipan cause weight gain or weight loss?

Regulatory documents list a general adverse reaction category of 'weight changes.' This indicates that alterations in weight are recognized as a possible effect of the drug.


Q: What happens if I stop taking Disipan suddenly?

The drug’s therapeutic effects are dependent on its presence in the body. Official patient information suggests that when the drug is discontinued, the effects may wear off after approximately 15 hours, reflecting its pharmacological duration of action.


Q: Can I use Disipan if I am also taking herbal supplements?

Regulatory guidance stresses the importance of informing a healthcare professional of all concomitant medications and supplements. This is necessary because interactions, such as those that could increase the risk of bleeding or other serious side effects, may occur with unlisted substances.


Q: Is it normal to feel anxious when first starting Disipan?

Anxiety is listed as a possible adverse reaction of the drug in official regulatory documents. This information forms part of the full safety profile reviewed by prescribers.


Q: Can Disipan affect sleep patterns?

Adverse reactions in the nervous system are documented in official labeling. These reactions include somnolence (drowsiness), insomnia (difficulty sleeping), and dream abnormalities.


Q: Can Disipan interfere with birth control pills?

Official regulatory information does not document a direct interaction with the hormonal action of contraceptives. However, it is noted that severe gastrointestinal adverse reactions, such as vomiting or diarrhea, may prevent oral birth control pills from being fully absorbed, potentially reducing their effectiveness.

How should Disipan be stored and disposed of?

How to Store and Dispose of Disipan

Official regulatory guidelines define specific conditions for the storage, handling, and disposal of Disipan to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Prohibitions Do not freeze. Must be protected from excessive heat and humidity.
Protection Keep the medicine in its original, sealed container, protected from moisture and light.
Children Keep Disipan, like all medicines, out of the sight and reach of children.

Disposal Instructions

Unused or expired Disipan must be disposed of according to local pharmaceutical waste regulations. It is strictly prohibited to dispose of the medication by pouring it down a sink, drain, or flushing it down a toilet, as stated in environmental guidelines for drug waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Disipan found in:

A-Z Index: